Cancer is among the leading causes of deaths worldwide. The challenge in treating cancer is changing every day with the new findings. memo-inOncology provides oncology and haematology specialists with the latest information on cancer research.

We are very thankful for the great unrestricted medical education grants by Apellis, BeiGene and Boehringer Ingelheim, three of the leading companies in the field of oncology and haematology.


Patients with rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia (AIHA) suffer from a premature breakdown of red blood cells causing loss of hemoglobin and in some cases severe anemia. Currently, these patients have limited treatment options. Apellis is committed to improving the lives of patients impacted by these rare diseases and many others with their pioneering targeted C3 immunotherapies.


Each year, millions of people are diagnosed with cancer around the world. Although there has been a considerable improvement in therapeutic options against cancer, it still remains one of the major causes of death worldwide. BeiGene is dedicated to discovering, innovating and developing better treatment against cancer to create a lasting impact on the patients with a mission to become a global leader in oncology research.

Boehringer Ingelheim in Oncology

Cancer is a major global public health problem and despite considerable advances in disease awareness, diagnosis and treatment, it remains an area of significant unmet medical need. Boehringer Ingelheim has a long-term commitment to delivering tomorrow’s cancer therapies by discovering and developing novel treatment options that combine ground-breaking science with high therapeutic value for patients.